"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Review article

Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder: A Systematic Review of Randomized Clinical Trials


Melatonin is a hormone produced by the pineal gland and is available over the counter for treating sleep problems in the pediatric population. We conducted a systematic review of randomized clinical trials (RCTs) on MEDLINE and included six studies that met our inclusion criteria. RCTs were conducted in patients from two to 18 years of age with a diagnostic and statistical manual of mental disorders (DSM)-IV diagnosis of autism spectrum disease (ASD) and/or attention-deficit hyperactivity disorder (ADHD) in both short-term and long-term RCTs ranging from eight-week to 52-week studies. The mean difference in the children’s sleep disorder showed statistically significant improvement in sleep duration and sleep latency onset compared to the placebo. Overall, a high response rate was observed in the melatonin group compared to the placebo in treating sleep problems in children. Melatonin is a well-tolerated and safe medication in the dose range of 2-10 mg/day in the child and adolescent population.

Introduction & Background

Sleep problems are increasingly becoming prevalent in children, as recent data found that about 50% of children from four to 12 years old have different sleep issues [1]. Sleep disturbances co-occur with psychiatric disorders including attention-deficit hyperactivity disorder (ADHD), autism spectrum disease (ASD), anxiety disorders, and major depressive disorder (MDD) [2]. As per a recent nationwide study, boys with ASD have two times higher likelihood of comorbid ADHD, with prevalence in white adolescents [3].

A higher proportion of patients with ASD have difficulty in sleep onset (53%), restless sleep (40%), nighttime awakening (34%), and difficulty in arousal from sleep (32%) [4]. The prevalence of sleep problems in ADHD patients is 73.3%, ranging from mild sleep disturbances (28.5%) to moderate and severe sleep disturbances (44.8%) such as frequent nighttime awakening, difficulty falling asleep, and circadian rhythm disturbance [5]. The prevalence of sleep problems in MDD is about 72.7% including insomnia, hypersomnia, or both, and children with anxiety disorders have nightmares, tiredness without exertion, and trouble sleeping [6-8].

Comorbid sleep problems have an impact on the daily functionality of children by an increase in externalizing and internalizing behaviors and an increase in autistic-like behaviors. Also, an increase in emotional and hyperactive symptoms can lead to impairment in academic and social functioning and maintaining relationships [7,9-10]. As these problems have a greater impact on a child’s growth and development, it is very important to diagnose and intervene at an earlier stage.

Based on past studies, non-pharmacologic treatment for sleep problems in children with psychiatric disorders includes behavioral therapy, like graduated extinction, bedtime routine, scheduled awakening, positive routine, and parent education [11-13]. Among pharmacological interventions, the most commonly used medications in the pediatric population are melatonin, trazodone, benzodiazepines, and antidepressants [11-13].

In our systematic review, we will do a qualitative synthesis of past randomized controlled trials (RCTs) conducted on melatonin in the pediatric population and to evaluate the overall efficacy and safety of melatonin for managing insomnia in ASD and neurodevelopmental disorder.


Study search strategy and selection

The MEDLINE database was used to identify clinical trials, clinical studies, multicenter studies, or observational studies published in English from April 19, 2010 to April 15, 2020 with MeSH terms "child" or "adolescent". The search strings were "melatonin" and "autism" or "autistic spectrum" or "developmental disorders" that yielded 79 studies. The screening was done independently by two authors (RSP, TP) using the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement (PRISMA) guidelines. The titles and abstracts were screened, based on the purpose of our study objective, and finally included seven studies. After reading the full text, a total of six studies met the criteria for our systematic review and were included as shown in Figure 1.

Mechanism of action

Melatonin or 5-methoxy N-acetyltryptamine is synthesized by the pineal gland from amino acid tryptophan by the first hydroxylation and then decarboxylation to form serotonin [14]. Melatonin production in the body is increased during darkness and reduced in light and so controls daily sleep and wakeful cycle [15]. Melatonin acts via MT1 receptors present in the suprachiasmatic nucleus (SCN) and controls the circadian rhythm [16].

Melatonin acts via MT1 G-protein coupled receptor that is pertussis toxin (PTX)-sensitive (Gi) and PTX insensitive (Gq). Activation of PTX-sensitive receptors inhibits cAMP, protein kinase A (PKA), and cAMP-responsive element-binding formation (CREB) [17]. SCN melatonin inhibits phosphorylation CREB, which leads to a change in circadian rhythm [18-19]. Similar to the MT1, MT2 receptor also inhibits the cAMP formation and cGMP formation. MT2 receptor interacts with diacylglycerol increases protein kinase C (PKC) in SCN, which affects the circadian clock [20].


Five studies conducted in an outpatient setting evaluated the efficacy of melatonin on sleep patterns in ASD [21-25]. Double-blinded-RCT (DB-RCT) conducted by Maras et al. included 95 pediatric patients with ASD and 51 patients received prolonged-release melatonin (2-10 mg/day) for 52 weeks and compared with placebo (N = 44). There was a statistically significant mean difference in the reduction of sleep latency (P<0.001) [21]. Similar results were also seen in a short-term study conducted by Gringras et al. [22]. An overview of the study design of included RCTs in shown in Table 1.

Study Study details Melatonin Control
Demographic Diagnosis Trial N Dosage N Dosage
Malow et al. Total N: 23 Age: 3-12 years ASD   Length: 14 weeks,  OP setting 23  1-6 mg None
Cortesi et al. Total N:66 Age: 4-10 years ASD Length: 12 weeks,  OP setting 34   3 mg* 32   Similar dosage of melatonin
Gringras et al. Total N: 119 Age: 2-17 years ASD Length: 13 weeks, OP setting 58   2-5 mg 61 Similar dosage of placebo
Maras et al. Total N: 95 Age: 2-17 years ASD Length: 52 weeks,  OP setting 51 2-10 mg 44 Similar dosage of placebo
Schroder et al. Total N: 119 Age: 2-17 years ASD Length: 13 weeks,  OP setting 58 2-5mg 61 Similar dosage of placebo
Mohammadi et al. Total N: 50 Age: 7-12 years ASD and ADHD Length: 8 weeks,  OP setting 26 3-6 mg* 24 MTP only

Cortesi et al. included 66 children (age, 4-10 years) with ASD in their DB-RCT and found that patients on both cognitive-behavioral therapy (CBT) and melatonin improved significantly compared to those in the melatonin-only group in terms of reduction in sleep onset latency and wakefulness after sleep onset, and increase in total sleep duration [23]. Schroder et al. found that ASD patients managed with prolonged release of melatonin showed improvement in externalizing behavior. This was measured by the strength and difficulty questionnaire (SDQ) with a treatment difference of -0.74 but was statistically not significant (P = 0.076) [25]. This study did find that melatonin at a higher dose above 10 mg is also not efficacious in improving sleep quality [25].

DB-RCT conducted by Mohammadi et al. in children with ADHD and ASD (N = 50) showed that melatonin did not show statistically significant improvement in total duration of sleep compared to control groups that did not receive melatonin (P = 0.19) [26]. Only one study did not have a placebo group, as Malow et al. compared the pre- and post-treatment scores for children's sleep habit questionnaire [24]. They found a statistically significant improvement in sleep onset, total sleep duration, and reduced night walking, but no significant difference in sleep anxiety and parasomnias [24]. Outcomes of sleep quality between melatonin and control groups have been described in Table 2.

Study Outcome Melatonin Control P-value
Pre-Rx score: mean (SD) Post-Rx score: mean (SD) Pre-Rx score: mean (SD) Post-Rx score: mean (SD)
Malow et al.* Sleep onset delay  2.6(0.6) 1.3(0.6) none <0.0001
Sleep duration 6.4(1.8) 3.7(1.3) <0.0001
Sleep total 55.2(6.9) 45.1(4.7) <0.0001
Sleep anxiety 6.8 (1.9) 6.3 (1.7) 0.270
Night walking 5.3 (1.9) 4.3 (1.4) 0.023
parasomnia 9.7 (2.0) 9.2 (2.1) 0.780
Sleep-disordered breathing 3.8 (1.2) 3.5 (0.6) 0.170
Daytime sleepiness 14.1 (2.4) 12.6 (2.7) 0.129
Bedtime resistance 10.7 (4.2) 8.3 (2.3) 0.008
Cortesi et al. Sleep total (minutes) 410.3 (45.1) 481.1 (33.2) 413.0 (45.1) 416.2 (43.6) <0.001
Sleep onset latency (minutes) 81.2 (32.4)   45.2 (23.2) 78.2 (33.8) 79.6 (31.9) <0.001
WASO (minutes) 73.7 (45.0) 42.2 (22.4) 69.75 (45.21) 70.2 (42.8) <0.001
Gringras et al. Total sleep time (minutes) 457.2 508.8 (10.5) 459.9 478.6 (10.8) 0.034
Sleep latency (minutes) 95.2 57.3 (6.8) 98.8 86.2 (7.0) 0.011
Maras et al. Sleep latency (minutes) 95.2 46.6 (10.2) 98.8 65.2 (8.3) <0.001
Schroder et al. SDQ Mean difference -0.57 (0.3) Mean difference 0.16 (0.3) 0.076
Mohammadi et al. Total sleep duration (in hours) 8 8.5 8.8 8.3 0.19

Adverse events

Melatonin is safe and widely used for sleep disorders. As per a 52-week long-term study, the most common side effects with melatonin include fatigue (18.9%), vomiting (16.8%), mood swings (13.7%), and upper respiratory infection (10.5%) [21].

Limitations of studies

The studies mentioned in our systematic review had some limitations. RCT by Malow et al. did not compare the results of the melatonin group with placebo [24]. DB-RCT by Cortesi et al. was conducted for 12 weeks that only validates short-term efficacy of melatonin, but on the contrary, Maras et al. conducted DB-RCT for the 52-week period to justify melatonin’s long-term efficacy and safety [21,23]. We cannot generalize the study results in ASD with/without ADHD patients to children with other psychiatric illnesses. Also, participants were compliant with medication after receiving parental consent, which may not be the scenario in the general population. In DB-RCT by Schroder et al., no supporting evidence existed for change in internalizing behavior evaluated by caregivers; the small sample size was not efficiently powered to detect the difference in sleep effect and behavior [25]. In the DB-RCT by Gringras et al. sleep monitoring was measured by actigraphy due to refusal to wear the device by the patient [22]. RCT by Maras et al. was open-label and a follow-up study of Gringras et al. study, and so it is possible that the improvement in the intervention group could be due to the efficacy of melatonin versus spontaneous remission in this long-term study [21-22].


Patients with ASD and/or ADHD showed improvement in total sleep time, sleep latency and improved uninterrupted sleep with melatonin, and augmented by combination management with melatonin and CBT. There was an improvement in externalizing behavior and subsequent improvement in the caregiver’s quality of life. Melatonin is a well-tolerated and safe medication in the dose range of 2-10 mg/day in the child and adolescent population. The efficacy and safety were proved by both short-term and long-term DB-RCTs.


  1. Carter KA, Hathaway NE, Lettieri CF: Common sleep disorders in children. Am Fam Physician. 2014, 89:368-377.
  2. Huhdanpaa H, Klenberg L, Westerinen H, Fontell T, Aronen ET: Sleep and psychiatric symptoms in young child psychiatric outpatients. Clin Child Psychol Psychiatry. 2018, 23:77-95. 10.1177/1359104517718366
  3. Ashraf S, Eskander N, Ceren Amuk O, Patel RS: Do demographics and comorbidities act as predictors of co-diagnosis of attention-deficit/hyperactivity disorder in autism spectrum disorder?. Cureus. 2020, 12:7798. 10.7759/cureus.7798
  4. Gail Williams P, Sears LL, Allard A: Sleep problems in children with autism. J Sleep Res. 2004, 13:265-268. 10.1111/j.1365-2869.2004.00405.x
  5. Sung V, Hiscock H, Sciberras E, Efron D: Sleep problems in children with attention-deficit/hyperactivity disorder: prevalence and the effect on the child and family. Arch Pediatr Adolesc Med. 2008, 162:336-342. 10.1001/archpedi.162.4.336
  6. Liu X, Buysse DJ, Gentzler AL, et al.: Insomnia and hypersomnia associated with depressive phenomenology and comorbidity in childhood depression. Sleep. 2007, 30:83-90. 10.1093/sleep/30.1.83
  7. Alfano CA, Beidel DC, Turner SM, Lewin DS: Preliminary evidence for sleep complaints among children referred for anxiety. Sleep Med. 2006, 7:467-473. 10.1016/j.sleep.2006.05.002
  8. Forbes EE, Bertocci MA, Gregory AM, Ryan ND, Axelson DA, Birmaher B, Dahl RE: Objective sleep in pediatric anxiety disorders and major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47:148-155. 10.1097/chi.0b013e31815cd9bc
  9. Sikora DM, Johnson K, Clemons T, Katz T: The relationship between sleep problems and daytime behavior in children of different ages with autism spectrum disorders. Pediatrics. 2012, 130 Suppl, 2:83-90. 10.1542/peds.2012-0900F
  10. Allik H, Larsson JO, Smedje H: Insomnia in school-age children with Asperger syndrome or high-functioning autism. BMC Psychiatry. 2006, 6:18. 10.1186/1471-244X-6-18
  11. Taylor DJ, Roane BM: Treatment of insomnia in adults and children: a practice-friendly review of research. J Clin Psychol. 2010, 66:1137-1147. 10.1002/jclp.20733
  12. Moturi S, Avis K: Assessment and treatment of common pediatric sleep disorders. Psychiatry (Edgmont). 2010, 7:24-37.
  13. van der Heijden KB, Stoffelsen RJ, Popma A, Swaab H: Sleep, chronotype, and sleep hygiene in children with attention-deficit/hyperactivity disorder, autism spectrum disorder, and controls. Eur Child Adolesc Psychiatry. 2018, 27:99-111. 10.1007/s00787-017-1025-8
  14. Axelrod J, Weissbach H: Enzymatic O-methylation of N-acetylserotonin to melatonin. Science. 1960, 131:1312. 10.1126/science.131.3409.1312
  15. Touitou Y: [Melatonin: hormone and medication]. C R Seances Soc Biol Fil. 1998, 192:643-657.
  16. Dubocovich ML, Benloucif S, Masana MI: Melatonin receptors in the mammalian suprachiasmatic nucleus. Behav Brain Res. 1996, 73:141-147. 10.1016/0166-4328(96)00086-1
  17. Witt-Enderby PA, Masana MI, Dubocovich ML: Physiological exposure to melatonin supersensitizes the cyclic adenosine 3',5'-monophosphate-dependent signal transduction cascade in chinese hamster ovary cells expressing the human mt1 melatonin receptor. Endocrinology. 1998, 139:3064-3071. 10.1210/endo.139.7.6102
  18. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, Weaver DR: Targeted disruption of the mouse mel(1b) melatonin receptor. Mol Cell Biol. 2003, 23:1054-1060. 10.1128/mcb.23.3.1054-1060.2003
  19. von Gall C, Weaver DR, Kock M, Korf HW, Stehle JH: Melatonin limits transcriptional impact of phosphocreb in the mouse scn via the mel1a receptor. Neuroreport. 2000, 11:1803-1807. 10.1097/00001756-200006260-00002
  20. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML: Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001, 280:110-118. 10.1152/ajpcell.2001.280.1.C110
  21. Maras A, Schroder CM, Malow BA, et al.: Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018, 28:699-710. 10.1089/cap.2018.0020
  22. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL: Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017, 56:948-957. 10.1016/j.jaac.2017.09.414
  23. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D: Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012, 21:700-709. 10.1111/j.1365-2869.2012.01021.x
  24. Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, Burnette C: Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012, 42:1729-1737. 10.1007/s10803-011-1418-3
  25. Schroder CM, Malow BA, Maras A, et al.: Pediatric prolonged-release melatonin for sleep in children with autism spectrum disorder: impact on child behavior and caregiver's quality of life. J Autism Dev Disord. 2019, 49:3218-3230. 10.1007/s10803-019-04046-5
  26. Mohammadi MR, Mostafavi SA, Keshavarz SA, et al.: Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iran J Psychiatry. 2012, 7:87-92.
Review article

Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder: A Systematic Review of Randomized Clinical Trials

Author Information

Tarun Parvataneni

Psychiatry, Siddavanahalli Nijalingappa Medical College and HSK Hospital and Research Centre, Bagalkot, IND

Sushma Srinivas

Psychiatry, A.J. Institute of Medical Sciences and Research Centre, Mangalore, IND

Kaushal Shah

Psychiatry, Griffin Memorial Hospital, Norman, USA

Rikinkumar S. Patel Corresponding Author

Psychiatry, Griffin Memorial Hospital, Norman, USA

Ethics Statement and Conflict of Interest Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Review article

Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder: A Systematic Review of Randomized Clinical Trials

Figures etc.


Scholary Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.